Skip to main content
SpringerLink
Log in

Cannabis for the Treatment of Epilepsy: an Update

  • Epilepsy (C Bazil, Section Editor)
  • Published:
Current Neurology and Neuroscience Reports Aims and scope Submit manuscript

Abstract

Purpose of Review

For millennia, there has been interest in the use of cannabis for the treatment of epilepsy. However, it is only recently that appropriately powered controlled studies have been completed. In this review, we present an update on the research investigating the use of cannabidiol (CBD), a non-psychoactive component of cannabis, in the treatment of epilepsy.

Recent Findings

While the anticonvulsant mechanism of action of CBD has not been entirely elucidated, we discuss the most recent data available including its low affinity for the endocannabinoid receptors and possible indirect modulation of these receptors via blocking the breakdown of anandamide. Additional targets include activation of the transient receptor potential of vanilloid type-1 (TRPV1), antagonist action at GPR55, targeting of abnormal sodium channels, blocking of T-type calcium channels, modulation of adenosine receptors, modulation of voltage-dependent anion selective channel protein (VDAC1), and modulation of tumor necrosis factor alpha release. We also discuss the most recent studies on various artisanal CBD products conducted in patients with epilepsy in the USA and internationally. While a high percentage of patients in these studies reported improvement in seizures, these studies were either retrospective or conducted via survey. Dosage/preparation of CBD was either unknown or not controlled in the majority of these studies. Finally, we present data from both open-label expanded access programs (EAPs) and randomized placebo-controlled trials (RCTs) of a highly purified oral preparation of CBD, which was recently approved by the FDA in the treatment of epilepsy. In the EAPs, there was a significant improvement in seizure frequency seen in a large number of patients with various types of treatment-refractory epilepsy. The RCTs have shown significant seizure reduction compared to placebo in patients with Dravet syndrome and Lennox-Gastaut syndrome. Finally, we describe the available data on adverse effects and drug-drug interactions with highly purified CBD. While this product is overall well tolerated, the most common side effects are diarrhea and sedation, with sedation being much more common in patients taking concomitant clobazam. There was also an increased incidence of aspartate aminotransferase and alanine aminotransferase elevations while taking CBD, with many of the patients with these abnormalities also taking concomitant valproate. CBD has a clear interaction with clobazam, significantly increasing the levels of its active metabolite N-desmethylclobazam in several studies; this is felt to be due to CBD’s inhibition of CYP2C19. EAP data demonstrate other possible interactions with rufinamide, zonisamide, topiramate, and eslicarbazepine. Additionally, there is one case report demonstrating need for warfarin dose adjustment with concomitant CBD.

Summary

Understanding of CBD’s efficacy and safety in the treatment of TRE has expanded significantly in the last few years. Future controlled studies of various ratios of CBD and THC are needed as there could be further therapeutic potential of these compounds for patients with epilepsy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance

  1. Maa E, Figi P. The case for medical marijuana in epilepsy. Epilepsia. 2014;55:783–6.

    Article  PubMed  Google Scholar 

  2. Szaflarski JP, Bebin EM. Cannabis, cannabidiol, and epilepsy--from receptors to clinical response. Epilepsy Behav. 2014;41:277–82.

    Article  PubMed  Google Scholar 

  3. Gaston TE, Friedman D. Pharmacology of cannabinoids in the treatment of epilepsy. Epilepsy Behav. 2017;70:313–8.

    Article  PubMed  Google Scholar 

  4. Pertwee RG, Cascio MG. Known pharmacological actions of delta-9-tetrahydrocannabinol and of four other chemical constituents of cannabis that activate cannabinoid receptors. In: Pertwee RG, editor. Handbook of cannabis. Oxford: Oxford University Press; 2014. p. 115.

    Chapter  Google Scholar 

  5. Pertwee RG. The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: delta9-tetrahydrocannabinol, cannabidiol and delta9-tetrahydrocannabivarin. Br J Pharmacol. 2008;153:199–215.

    Article  CAS  Google Scholar 

  6. Wallace MJ, Blair RE, Falenski KW, Martin BR, DeLorenzo RJ. The endogenous cannabinoid system regulates seizure frequency and duration in a model of temporal lobe epilepsy. J Pharmacol Exp Ther. 2003;307:129–37.

    Article  CAS  PubMed  Google Scholar 

  7. Wallace MJ, Martin BR, DeLorenzo RJ. Evidence for a physiological role of endocannabinoids in the modulation of seizure threshold and severity. Eur J Pharmacol. 2002;452:295–301.

    Article  CAS  PubMed  Google Scholar 

  8. Wallace MJ, Wiley JL, Martin BR, DeLorenzo RJ. Assessment of the role of CB1 receptors in cannabinoid anticonvulsant effects. Eur J Pharmacol. 2001;428:51–7.

    Article  CAS  PubMed  Google Scholar 

  9. McPartland JM, Duncan M, Di Marzo V, Pertwee RG. Are cannabidiol and Delta(9) -tetrahydrocannabivarin negative modulators of the endocannabinoid system? A systematic review. Br J Pharmacol. 2015;172:737–53.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Perucca E. Cannabinoids in the treatment of epilepsy: hard evidence at last? J Epilepsy Res. 2017;7:61–76.

    Article  PubMed  PubMed Central  Google Scholar 

  11. Thomas A, Baillie GL, Phillips AM, Razdan RK, Ross RA, Pertwee RG. Cannabidiol displays unexpectedly high potency as an antagonist of CB1 and CB2 receptor agonists in vitro. Br J Pharmacol. 2007;150:613–23.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Bisogno T, Hanus L, De Petrocellis L, et al. Molecular targets for cannabidiol and its synthetic analogues: effect on vanilloid VR1 receptors and on the cellular uptake and enzymatic hydrolysis of anandamide. Br J Pharmacol. 2001;134:845–52.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. • Cleeren E, Casteels C, Goffin K, et al. Positron emission tomography imaging of cerebral glucose metabolism and type 1 cannabinoid receptor availability during temporal lobe epileptogenesis in the amygdala kindling model in rhesus monkeys. Epilepsia. 2018;59:959–70. This study documents the relationship between epileptogenesis and endocannabinoid system through all stages of epilepsy development.

    Article  CAS  PubMed  Google Scholar 

  14. Szaflarski J. The highs and lows of the endocannabinoid system – Another piece to the epilepsy puzzle? Epilepsy Curr. 2018;in print.

  15. Vilela LR, Lima IV, Kunsch EB, Pinto HPP, de Miranda AS, Vieira ÉLM, et al. Anticonvulsant effect of cannabidiol in the pentylenetetrazole model: pharmacological mechanisms, electroencephalographic profile, and brain cytokine levels. Epilepsy Behav. 2017;75:29–35.

    Article  PubMed  Google Scholar 

  16. Naziroglu M. TRPV1 channel: a potential drug target for treating epilepsy. Curr Neuropharmacol. 2015;13:239–47.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Ryberg E, Larsson N, Sjogren S, et al. The orphan receptor GPR55 is a novel cannabinoid receptor. Br J Pharmacol. 2007;152:1092–101.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Hurst K, Badgley C, Ellsworth T, Bell S, Friend L, Prince B, et al. A putative lysophosphatidylinositol receptor GPR55 modulates hippocampal synaptic plasticity. Hippocampus. 2017;27:985–98.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Kaplan JS, Stella N, Catterall WA, Westenbroek RE. Cannabidiol attenuates seizures and social deficits in a mouse model of Dravet syndrome. Proc Natl Acad Sci U S A. 2017;114:11229–34.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Patel RR, Barbosa C, Brustovetsky T, Brustovetsky N, Cummins TR. Aberrant epilepsy-associated mutant Nav1.6 sodium channel activity can be targeted with cannabidiol. Brain J Neurol. 2016;139:2164–81.

    Article  Google Scholar 

  21. Ross HR, Napier I, Connor M. Inhibition of recombinant human T-type calcium channels by Delta9-tetrahydrocannabinol and cannabidiol. J Biol Chem. 2008;283:16124–34.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  22. Devinsky O, Cilio MR, Cross H, Fernandez-Ruiz J, French J, Hill C, et al. Cannabidiol: pharmacology and potential therapeutic role in epilepsy and other neuropsychiatric disorders. Epilepsia. 2014;55:791–802.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. During MJ, Spencer DD. Adenosine: a potential mediator of seizure arrest and postictal refractoriness. Ann Neurol. 1992;32:618–24.

    Article  CAS  PubMed  Google Scholar 

  24. Rimmerman N, Ben-Hail D, Porat Z, Juknat A, Kozela E, Daniels MP, et al. Direct modulation of the outer mitochondrial membrane channel, voltage-dependent anion channel 1 (VDAC1) by cannabidiol: a novel mechanism for cannabinoid-induced cell death. Cell Death Dis. 2013;4:e949.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. Kozela E, Juknat A, Vogel Z. Modulation of astrocyte activity by cannabidiol, a nonpsychoactive cannabinoid. Int J Mol Sci. 2017;18

    Article  PubMed Central  Google Scholar 

  26. Pelz MC, Schoolcraft KD, Larson C, Spring MG, Lopez HH. Assessing the role of serotonergic receptors in cannabidiol’s anticonvulsant efficacy. Epilepsy Behav. 2017;73:111–8.

    Article  PubMed  Google Scholar 

  27. • Sulak D, Saneto R, Goldstein B. The current status of artisanal cannabis for the treatment of epilepsy in the United States. Epilepsy Behav. 2017;70:328–33. While open label, this study discusses various aspects of treating epilepsy with artisanal cannabis products in various settings.

    Article  PubMed  Google Scholar 

  28. Press CA, Knupp KG, Chapman KE. Parental reporting of response to oral cannabis extracts for treatment of refractory epilepsy. Epilepsy Behav. 2015;45:49–52.

    Article  PubMed  Google Scholar 

  29. Hussain SA, Zhou R, Jacobson C, Weng J, Cheng E, Lay J, et al. Perceived efficacy of cannabidiol-enriched cannabis extracts for treatment of pediatric epilepsy: a potential role for infantile spasms and Lennox-Gastaut syndrome. Epilepsy Behav. 2015;47:138–41.

    Article  PubMed  Google Scholar 

  30. Tzadok M, Uliel-Siboni S, Linder I, Kramer U, Epstein O, Menascu S, et al. CBD-enriched medical cannabis for intractable pediatric epilepsy: the current Israeli experience. Seizure. 2016;35:41–4.

    Article  PubMed  Google Scholar 

  31. Hausman-Kedem M, Menascu S, Kramer U. Efficacy of CBD-enriched medical cannabis for treatment of refractory epilepsy in children and adolescents - an observational, longitudinal study. Brain and Development. 2018;40:544–51.

    Article  PubMed  Google Scholar 

  32. Suraev AS, Todd L, Bowen MT, Allsop DJ, McGregor IS, Ireland C, et al. An Australian nationwide survey on medicinal cannabis use for epilepsy: history of antiepileptic drug treatment predicts medicinal cannabis use. Epilepsy Behav. 2017;70:334–40.

    Article  PubMed  Google Scholar 

  33. Suraev A, Lintzeris N, Stuart J, Kevin RC, Blackburn R, Richards E, et al. Composition and use of cannabis extracts for childhood epilepsy in the Australian community. Sci Rep. 2018;8:10154.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  34. Devinsky O, Marsh E, Friedman D, Thiele E, Laux L, Sullivan J, et al. Cannabidiol in patients with treatment-resistant epilepsy: an open-label interventional trial. Lancet Neurol. 2016;15:270–8.

    Article  CAS  PubMed  Google Scholar 

  35. • Szaflarski JP, Bebin EM, Comi AM, et al. Long-term safety and treatment effects of cannabidiol in children and adults with treatment-resistant epilepsies: Expanded access program results. Epilepsia 2018;59:1540–1548. This open-label study documents the sustained response to cannabidiol over the duration of exposure.

    Article  CAS  PubMed  Google Scholar 

  36. Szaflarski JP, Bebin E, Cutter GR, et al. Cannabidiol improves seizure frequency and severity and reduces adverse events in an open-label prospective study. Epilepsy Behav. 2018; Accepted; In Press.

  37. Hess EJ, Moody KA, Geffrey AL, Pollack SF, Skirvin LA, Bruno PL, et al. Cannabidiol as a new treatment for drug-resistant epilepsy in tuberous sclerosis complex. Epilepsia. 2016;57:1617–24.

    Article  CAS  PubMed  Google Scholar 

  38. Devinsky O, Verducci C, Thiele EA, Laux LC, Patel AD, Filloux F, et al. Open-label use of Highly* purified CBD (Epidiolex®) in patients with CDKL5 deficiency disorder and Aicardi, Dup15q, and Doose syndromes. Epilepsy Behav. 2018;86:131–7.

    Article  PubMed  Google Scholar 

  39. Gofshteyn JS, Wilfong A, Devinsky O, Bluvstein J, Charuta J, Ciliberto MA, et al. Cannabidiol as a potential treatment for febrile infection-related epilepsy syndrome (FIRES) in the acute and chronic phases. J Child Neurol. 2017;32:35–40.

    Article  PubMed  Google Scholar 

  40. McCoy B, Wang L, Zak M, et al. A prospective open-label trial of CBD/THC cannabis oil in Dravet syndrome. Ann Clin Transl Neurol. in print.

  41. Gloss D, Vickrey B. Cannabinoids for epilepsy. Cochrane Database Syst Rev. 2014;3:CD009270.

    Google Scholar 

  42. Devinsky O, Patel AD, Thiele EA, Wong MH, Appleton R, Harden CL, et al. Randomized, dose-ranging safety trial of cannabidiol in Dravet syndrome. Neurology. 2018;90:e1204–11.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  43. • Devinsky O, Patel AD, Cross JH, et al. Effect of cannabidiol on drop seizures in the Lennox-Gastaut syndrome. N Engl J Med. 2018;378:1888–97. RCT of cannabidiol for the treatment of seizures associated with Lennox-Gastaut syndrome

    Article  CAS  PubMed  Google Scholar 

  44. Espay AJ, Norris MM, Eliassen JC, Dwivedi A, Smith MS, Banks C, et al. Placebo effect of medication cost in Parkinson disease: a randomized double-blind study. Neurology. 2015;84:794–802.

    Article  PubMed  PubMed Central  Google Scholar 

  45. Vandrey R, Raber JC, Raber ME, Douglass B, Miller C, Bonn-Miller MO. Cannabinoid dose and label accuracy in edible medical cannabis products. Jama. 2015;313:2491–3.

    Article  CAS  PubMed  Google Scholar 

  46. • Devinsky O, Cross JH, Laux L, et al. Trial of cannabidiol for drug-resistant seizures in the Dravet syndrome. N Engl J Med. 2017;376:2011–20. RCT of cannabidiol for the treatment of seizures associated with Dravet syndrome.

    Article  CAS  PubMed  Google Scholar 

  47. • Thiele EA, Marsh ED, French JA, et al. Cannabidiol in patients with seizures associated with Lennox-Gastaut syndrome (GWPCARE4): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2018;391:1085–96. RCT of cannabidiol for the treatment of seizures associated with Lennox-Gastaut syndrome.

    Article  CAS  PubMed  Google Scholar 

  48. Geffrey AL, Pollack SF, Bruno PL, Thiele EA. Drug-drug interaction between clobazam and cannabidiol in children with refractory epilepsy. Epilepsia. 2015;56:1246–51.

    Article  CAS  PubMed  Google Scholar 

  49. Jiang R, Yamaori S, Okamoto Y, Yamamoto I, Watanabe K. Cannabidiol is a potent inhibitor of the catalytic activity of cytochrome P450 2C19. Drug Metab Pharmacokinet. 2013;28:332–8.

    Article  CAS  PubMed  Google Scholar 

  50. • Gaston TE, Bebin EM, Cutter GR, Liu Y, Szaflarski JP. Interactions between cannabidiol and commonly used antiepileptic drugs. Epilepsia. 2017;58:1586–92. Detailed analysis of interactions of cannabidiol with common anti-seizure drugs.

    Article  CAS  PubMed  Google Scholar 

  51. Grayson L, Vines B, Nichol K, Szaflarski JP, Program UC. An interaction between warfarin and cannabidiol, a case report. Epilepsy Behav Case Rep. 2018;9:10–1.

    Article  PubMed  Google Scholar 

  52. Gaston TE, Liu Y, Cutter GR, Bebin E, Grayson LE, Szaflarski JP. Effect of pharmaceutical formulation of cannabidiol (CBD) on seizure frequency and severity does not appear to be dependent on drug-drug interactions with other anti-epileptic drugs. American Academy of Neurology Annual Meeting; 2018 25 April 2018; Los Angeles, CA.

Download references

Author information

Authors and Affiliations

  1. Department of Neurology, University of Alabama at Birmingham Epilepsy Center, Birmingham, AL, USA

    Tyler E. Gaston & Jerzy P. Szaflarski

  2. 312 Civitan International Research Center, 1719 6th Avenue South, CIRC 312, Birmingham, AL, 35294, USA

    Jerzy P. Szaflarski

Authors
  1. Tyler E. Gaston
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jerzy P. Szaflarski
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jerzy P. Szaflarski.

Ethics declarations

Conflict of Interest

Dr. Szaflarski reports personal fees from GW Pharmaceuticals; grants and personal fees from Serina Therapeutics, Inc., during the conduct of the study; personal fees from SK Life Sciences; personal fees from LivaNova Inc.; personal fees from Lundbeck; personal fees from NeuroPace Inc.; personal fees from Upsher-Smith Laboratories, Inc.; grants and personal fees from SAGE Pharmaceuticals; grants from UCB Pharma; grants from Biogen; and grants from Eisai Inc., outside the submitted work.

Dr. Gaston reports personal fees from GW Pharmaceuticals, during the conduct of the study.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Additional information

This article is part of the Topical Collection on Epilepsy

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Gaston, T.E., Szaflarski, J.P. Cannabis for the Treatment of Epilepsy: an Update. Curr Neurol Neurosci Rep 18, 73 (2018). https://doi.org/10.1007/s11910-018-0882-y

Download citation

  • Published:

  • DOI: https://doi.org/10.1007/s11910-018-0882-y

Keywords

Search

Navigation